AnaptysBio (NASDAQ:ANAB) had its target price decreased by SunTrust Banks from $125.00 to $93.00 in a research report report published on Monday, The Fly reports. SunTrust Banks currently has a buy rating on the biotechnology company’s stock. SunTrust Banks also issued estimates for AnaptysBio’s FY2020 earnings at ($4.73) EPS.
ANAB has been the subject of a number of other reports. Zacks Investment Research raised shares of AnaptysBio from a sell rating to a buy rating and set a $77.00 target price for the company in a report on Wednesday, March 6th. Credit Suisse Group lowered shares of AnaptysBio from an outperform rating to a neutral rating and dropped their price objective for the stock from $137.00 to $79.00 in a research note on Friday, June 21st. Cantor Fitzgerald reaffirmed a buy rating and set a $140.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 27th. Wedbush reiterated an outperform rating on shares of AnaptysBio in a research report on Friday, March 1st. Finally, Stifel Nicolaus set a $124.00 target price on AnaptysBio and gave the stock a buy rating in a research report on Wednesday, May 8th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $111.25.
ANAB stock opened at $53.76 on Monday. The firm has a fifty day simple moving average of $70.56. AnaptysBio has a fifty-two week low of $52.93 and a fifty-two week high of $110.00. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -21.50 and a beta of 1.98.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Sell-side analysts expect that AnaptysBio will post -3.76 EPS for the current fiscal year.
In other AnaptysBio news, insider Marco Londei sold 10,060 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the transaction, the insider now directly owns 32,437 shares in the company, valued at $2,369,847.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Hamza Suria sold 22,428 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The disclosure for this sale can be found here. Insiders own 14.00% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Diag Capital Management LP bought a new position in AnaptysBio in the fourth quarter worth about $95,000. Amundi Pioneer Asset Management Inc. bought a new position in AnaptysBio in the first quarter worth about $110,000. SG Americas Securities LLC bought a new position in AnaptysBio in the fourth quarter worth about $126,000. Bank of America Corp DE raised its holdings in AnaptysBio by 141.2% in the fourth quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 15,067 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in AnaptysBio in the first quarter worth about $290,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.